OBJECTIVES: Recent preclinical studies suggest that treating glioblastoma (GBM) with a combination of targeted chemotherapy and radiotherapy may enhance the anti-tumor effects of both therapies. However, the effects of these treatments on glioma growth and progression are poorly understood. METHODS: In this study, we have tested the effects of combination therapy in a mouse glioma model that utilizes a PDGF-IRES-Cre-expressing retrovirus to infect adult glial progenitors in mice carrying conditional deletions of Pten and p53. This model produces tumors with the histological features of GBM with 100% penetrance, making it a powerful system to test novel treatments. Sunitinib is an orally active, small molecule inhibitor of multiple receptor tyrosine kinases critical for tumor growth and angiogenesis, including PDGF receptors. We investigate the addition of Sunitinib to radiotherapy, and use bioluminescence imaging to characterize the effects of treatment on glioma growth and progression. RESULTS: Treating our PDGF-driven mouse model with either Sunitinib or high-dose radiation alone delayed tumor growth and had a modest but significant effect on survival, while treating with low-dose radiation alone failed to control glioma growth and progression. The addition of Sunitinib to low-dose radiation caused a modest, but significant delay in tumor growth. However, no significant survival benefit was seen as tumors progressed in 100% of animals. Histological analysis revealed a reduction in vascular proliferation and a marked increase in brain invasion. An additional study combining Sunitinib with high-dose radiation revealed a fatal toxicity despite individual monotherapies being well tolerated. DISCUSSION: These results show that the addition of Sunitinib to radiotherapy fails to significantly alter survival in GBM despite enhancement of the effects of radiation. Furthermore, an enhanced risk of toxicity associated with combined therapy must be considered in the design of future clinical studies.
OBJECTIVES: Recent preclinical studies suggest that treating glioblastoma (GBM) with a combination of targeted chemotherapy and radiotherapy may enhance the anti-tumor effects of both therapies. However, the effects of these treatments on glioma growth and progression are poorly understood. METHODS: In this study, we have tested the effects of combination therapy in a mouseglioma model that utilizes a PDGF-IRES-Cre-expressing retrovirus to infect adult glial progenitors in mice carrying conditional deletions of Pten and p53. This model produces tumors with the histological features of GBM with 100% penetrance, making it a powerful system to test novel treatments. Sunitinib is an orally active, small molecule inhibitor of multiple receptor tyrosine kinases critical for tumor growth and angiogenesis, including PDGF receptors. We investigate the addition of Sunitinib to radiotherapy, and use bioluminescence imaging to characterize the effects of treatment on glioma growth and progression. RESULTS: Treating our PDGF-driven mouse model with either Sunitinib or high-dose radiation alone delayed tumor growth and had a modest but significant effect on survival, while treating with low-dose radiation alone failed to control glioma growth and progression. The addition of Sunitinib to low-dose radiation caused a modest, but significant delay in tumor growth. However, no significant survival benefit was seen as tumors progressed in 100% of animals. Histological analysis revealed a reduction in vascular proliferation and a marked increase in brain invasion. An additional study combining Sunitinib with high-dose radiation revealed a fatal toxicity despite individual monotherapies being well tolerated. DISCUSSION: These results show that the addition of Sunitinib to radiotherapy fails to significantly alter survival in GBM despite enhancement of the effects of radiation. Furthermore, an enhanced risk of toxicity associated with combined therapy must be considered in the design of future clinical studies.
Authors: James J Vredenburgh; Annick Desjardins; John P Kirkpatrick; David A Reardon; Katherine B Peters; James E Herndon; Jennifer Marcello; Leighann Bailey; Stevie Threatt; John Sampson; Allan Friedman; Henry S Friedman Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-30 Impact factor: 7.038
Authors: Robert J Griffin; Brent W Williams; Robert Wild; Julie M Cherrington; Heonjoo Park; Chang W Song Journal: Cancer Res Date: 2002-03-15 Impact factor: 12.701
Authors: Dirk B Mendel; A Douglas Laird; Xiaohua Xin; Sharianne G Louie; James G Christensen; Guangmin Li; Randall E Schreck; Tinya J Abrams; Theresa J Ngai; Leslie B Lee; Lesley J Murray; Jeremy Carver; Emily Chan; Katherine G Moss; Joshua O Haznedar; Juthamas Sukbuntherng; Robert A Blake; Li Sun; Cho Tang; Todd Miller; Sheri Shirazian; Gerald McMahon; Julie M Cherrington Journal: Clin Cancer Res Date: 2003-01 Impact factor: 12.531
Authors: Adam M Sonabend; Jonathan Yun; Liang Lei; Richard Leung; Craig Soderquist; Celina Crisman; Brian J Gill; Arthur Carminucci; Julia Sisti; Mike Castelli; Peter A Sims; Jeffrey N Bruce; Peter Canoll Journal: J Neurooncol Date: 2013-03-16 Impact factor: 4.130
Authors: Sylvia Moeckel; Katharina Meyer; Petra Leukel; Fabian Heudorfer; Corinna Seliger; Christina Stangl; Ulrich Bogdahn; Martin Proescholdt; Alexander Brawanski; Arabel Vollmann-Zwerenz; Markus J Riemenschneider; Anja-Katrin Bosserhoff; Rainer Spang; Peter Hau Journal: PLoS One Date: 2014-09-30 Impact factor: 3.240
Authors: Cynthia Wetmore; Vinay M Daryani; Catherine A Billups; James M Boyett; Sarah Leary; Rachel Tanos; Kelly C Goldsmith; Clinton F Stewart; Susan M Blaney; Amar Gajjar Journal: Cancer Med Date: 2016-04-25 Impact factor: 4.452
Authors: Giovanni Luca Gravina; Andrea Mancini; Francesco Marampon; Alessandro Colapietro; Simona Delle Monache; Roberta Sferra; Flora Vitale; Peter J Richardson; Lee Patient; Stephen Burbidge; Claudio Festuccia Journal: J Hematol Oncol Date: 2017-01-05 Impact factor: 17.388
Authors: Vivek Subbiah; Funda Meric-Bernstam; Gordon B Mills; Kenna R Mills Shaw; Ann Marie Bailey; Priya Rao; John F Ward; Lance C Pagliaro Journal: J Hematol Oncol Date: 2014-08-01 Impact factor: 17.388